Trazodone and Finasteride Interaction: Safety, Risks, and Clinical Guidance

What each drug is, so it isn't confused with a relative

Trazodone is FDA-approved for major depressive disorder in adults; low-dose use for insomnia (commonly 25 to 100 mg) is off-label. It belongs to the serotonin antagonist and reuptake inhibitor (SARI) class and is metabolized largely through CYP3A4 into an active metabolite, meta-chlorophenylpiperazine (mCPP).

Finasteride is a 5-alpha-reductase inhibitor available in two FDA-approved strengths: 1 mg (Propecia) for androgenetic alopecia in men, based on trial evidence including a large randomized study of finasteride in male pattern hair loss, and 5 mg (Proscar) for benign prostatic hyperplasia, based on trial evidence including the PLESS study. Neither strength is approved for use in women who are or may become pregnant.

The question worth asking

The two drugs are not a dangerous chemical combination. The useful clinical question is whether a patient taking both should be monitored differently than a patient on either drug alone, given that both independently list sexual side effects and one (finasteride) has a plausible, though unproven, link to mood-relevant neurosteroids. That framing, not a simple "is this safe," is what should guide the rest of this page.

Pharmacokinetics: CYP3A4 overlap without a clinically meaningful interaction

Trazodone is extensively metabolized through CYP3A4. Strong CYP3A4 inhibitors, such as ketoconazole or ritonavir, can raise trazodone exposure substantially, and the FDA label for trazodone advises caution and possible dose reduction in that setting.

Finasteride is also processed in part through CYP3A4, but published metabolic data do not show finasteride acting as a clinically significant CYP3A4 inhibitor or inducer at therapeutic doses. Because of that, finasteride is not expected to meaningfully change trazodone's plasma levels, and trazodone is not expected to alter finasteride's clearance. No dedicated pharmacokinetic co-administration study of the two drugs has been published, so this conclusion rests on each drug's independent metabolic profile rather than on a trial designed to test the pair directly. Standard drug-interaction references used in practice (Lexicomp, Micromedex, and similar clinical decision-support tools) are generally consistent with treating this as a low pharmacokinetic-risk pairing, but that classification should be confirmed against the tool your pharmacy or clinic actually uses, since database content changes.

Sexual side effects: where the overlap actually lives

This is the part of the interaction that matters clinically.

Trazodone can cause priapism through alpha-1-adrenergic blockade in penile smooth muscle, which is why its FDA label carries a specific priapism warning and instructs patients to seek immediate care for an erection lasting longer than four hours. Older pharmacovigilance and case-review literature on psychotropic-associated priapism describes trazodone as the antidepressant most frequently implicated, though modern incidence figures are not tightly established and should be treated as approximate rather than precise. At antidepressant doses (150 to 300 mg/day) trazodone is also associated with decreased libido and erectile difficulty; at low sleep doses this appears less common but is not eliminated.

Finasteride is associated with erectile dysfunction and decreased libido on its own FDA label. A subset of patients report sexual, neurological, or psychological symptoms that persist after stopping the drug, sometimes referred to as post-finasteride syndrome; the mechanism and even the clinical boundaries of this entity remain debated and are not settled by current evidence.

No published trial has measured the combined rate of sexual dysfunction when trazodone and finasteride are taken together. Because of that, this article does not offer a numeric combined-risk estimate. What can be said is qualitative and directional: a patient starting both drugs is starting two independent risk factors for the same category of side effect, so a symptom that appears after starting the second drug is worth attributing correctly rather than assumed to be from whichever drug was started most recently.

The neurosteroid and mood question

Finasteride inhibits 5-alpha-reductase, an enzyme family involved in the synthesis pathway that ultimately produces allopregnanolone, a neurosteroid that acts as a positive modulator at GABA-A receptors and is implicated in mood regulation. Brexanolone, an FDA-approved treatment for postpartum depression, is itself a synthetic form of allopregnanolone, which illustrates that this neurosteroid pathway is clinically relevant to mood, not a fringe idea.

What is not established from the sources reviewed for this page is a direct, quantified demonstration that finasteride lowers allopregnanolone in a way that blunts trazodone's antidepressant effect in humans. An earlier version of this guidance cited a specific cerebrospinal-fluid finasteride study with a precise percentage reduction; that citation could not be verified as describing finasteride-treated men and has been removed rather than repeated. The neurosteroid mechanism connecting 5-alpha-reductase inhibition to mood is biologically plausible and is described in review literature on neuroactive steroids, but a finasteride-specific, trazodone-relevant clinical trial demonstrating a mood interaction has not been identified. Treat this as a theoretical concern that justifies watching mood scores, not as a proven drug interaction.

Practical step: for a patient on trazodone for depression who is starting finasteride, document a baseline depression severity score (for example PHQ-9) and recheck it in the 8-to-12-week range. If depressive symptoms worsen with no other clear cause, discuss a trial off finasteride before escalating the trazodone dose.

Priapism: separating trazodone's known risk from finasteride's non-role

Trazodone's priapism warning stems from its alpha-1-adrenergic blocking activity, which prevents normal detumescence. Finasteride does not act on this receptor pathway and has not been shown to add to trazodone's priapism risk. The patient instruction is the same as for trazodone alone: any erection lasting more than four hours is a medical emergency requiring same-day evaluation, and adding finasteride does not change that threshold.

A monitoring approach, since no guideline body has issued one specific to this pair

No professional body (the American Urological Association, the American Psychiatric Association, or the Endocrine Society) has published a monitoring protocol specific to trazodone plus finasteride. The following draws on each drug's individual labeling and general principles for managing overlapping side-effect profiles; it is a site judgment, not a guideline recommendation.

Before starting the combination: note current sexual function (a structured tool such as the IIEF-5 is one option), a baseline depression severity score if trazodone is being used for depression, PSA if finasteride 5 mg is being used for BPH, and a full medication list to check for other CYP3A4-active drugs that could independently raise trazodone levels.

At 4 weeks: ask specifically about sexual function and sleep quality; patients often do not volunteer sexual side effects unless asked directly, which is a recurring theme in the clinical literature on finasteride-associated sexual dysfunction.

At 8 to 12 weeks: repeat the depression severity score if trazodone is being used for a mood indication.

Ongoing: reassess whether both medications are still needed at routine visits, since finasteride for hair loss is an elective, cosmetic indication that can be stopped without medical urgency if it appears to be contributing to a problem.

If new sexual dysfunction appears: a stepwise approach, pausing one drug and reassessing before touching the second, is generally more informative than stopping both simultaneously. If finasteride is being used for hair loss rather than BPH, it is usually the more reasonable one to trial off first. If trazodone is being used only for insomnia, switching to a non-serotonergic option (for example melatonin, low-dose doxepin, or an orexin receptor antagonist such as suvorexant) may resolve the issue without touching the finasteride regimen; this is a treatment-substitution decision that should be made with the prescriber, not a self-directed dosing change.

Other trazodone interactions that carry more weight than this one

Patients on trazodone and finasteride are often on additional medications, and several trazodone interactions are more clinically urgent than the finasteride pairing.

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) can meaningfully raise trazodone exposure; the FDA label recommends considering a lower trazodone dose in that setting.

MAOIs are contraindicated with trazodone because of serotonin syndrome risk; the label specifies a 14-day washout before starting trazodone after stopping an MAOI.

QT-prolonging drugs (certain antiemetics, some fluoroquinolones, Class III antiarrhythmics) combined with trazodone raise torsades de pointes risk; the label advises ECG monitoring in patients with cardiac risk factors.

CNS depressants (benzodiazepines, opioids, alcohol) add to trazodone's sedative effect; general psychiatric prescribing guidance recommends counseling patients about this combination regardless of finasteride use.

Special populations

Older adults taking finasteride for BPH and trazodone for insomnia carry an added consideration: trazodone's sedation and orthostatic hypotension can raise fall risk in this age group. This is a general geriatric prescribing caution rather than something specific to the finasteride combination, and dosing should be individualized with that in mind.

Hepatic impairment can slow clearance of both drugs. There is no published data on the combined effect of trazodone and finasteride specifically in patients with hepatic impairment; conservative trazodone dosing with slow titration is a reasonable, cautious default rather than an evidence-based protocol for this exact combination.

Depression versus insomnia-only use changes the risk-benefit calculation. If trazodone is treating a depressive disorder, it is likely the more clinically necessary drug and finasteride (especially the 1 mg cosmetic-indication strength) is the more discretionary one. If trazodone is being used only for sleep, alternatives that avoid serotonergic and sexual side effects exist and are worth discussing before assuming the finasteride has to go.

What the evidence does and does not show

Established: finasteride does not meaningfully inhibit or induce CYP3A4 and is not expected to raise trazodone levels. Both drugs independently carry FDA-labeled sexual side-effect warnings. Trazodone's priapism risk is mechanistically tied to alpha-1-adrenergic blockade, a pathway finasteride does not share.

Plausible but unproven: that combining the two drugs measurably increases the rate of sexual dysfunction beyond either drug alone. That finasteride's effect on 5-alpha-reductase-dependent neurosteroid synthesis could blunt trazodone's antidepressant benefit in some patients.

Not established: any specific combined numeric risk of sexual dysfunction for this pairing. Any human trial quantifying a finasteride-driven change in cerebrospinal allopregnanolone in men taking trazodone. A finasteride-specific contribution to trazodone-associated priapism.

Readers and clinicians should treat any precise combined-risk percentage for this pairing with skepticism until a study designed to measure it is published.

Evidence-status assessment: what to verify before relying on this pairing

Frequently asked questions

References

1. Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5-alpha reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. PubMed
2. FDA. Desyrel (trazodone hydrochloride) prescribing information. Label
3. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia (PLESS). N Engl J Med. 1998. PubMed
4. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998. PubMed
5. Melcangi RC, Giatti S, Garcia-Segura LM. Levels and actions of neuroactive steroids in the nervous system under physiological and pathological conditions. PubMed
6. FDA. Zulresso (brexanolone) prescribing information. Label
7. Thompson JW Jr, Ware MR, Blashfield RK. Psychotropic medication and priapism: a comprehensive review. PubMed
8. Irwig MS. Persistent sexual side effects of finasteride: could they be permanent? J Sex Med. 2012. PubMed
9. American Psychiatric Association. Practice Guideline for the Treatment of Major Depressive Disorder, Third Edition. NCBI Bookshelf